In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Voyager Therapeutics Inc (NASDAQ: VYGR), with a price target of $27. The company’s shares closed on Friday at $19.31.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 13.8% and a 63.2% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Alexion Pharmaceuticals, Rubius Therapeutics Inc, and Sarepta Therapeutics.
Currently, the analyst consensus on Voyager Therapeutics Inc is a Moderate Buy with an average price target of $30.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.91 and a one-year low of $11.54. Currently, Voyager Therapeutics Inc has an average volume of 446.6K.
Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of VYGR in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene theraphy programs include VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01.
